A first-in-human Phase I trial showed that Eli Lilly’s investigational oral lipoprotein(a) inhibitor muvalaplin was safe and could elicit sharp reductions in concentrations of cholesterol formation.
Posts
The FDA has placed a partial clinical hold on a Phase I study of Foghorn Therapeutics’ investigational protein degrader FHD-609 after a patient developed a grade 4 QTc prolongation event, the company announced Monday.
ALS is the 5,000-piece jigsaw puzzle of the therapeutic world. As the regulatory edges come together, new research pieces are also connecting.
Eliem Therapeutics is dropping a depression drug candidate and laying off 55% of staff in an attempt to stretch its cash runway, according to a Thursday press release.
TCR2 Therapeutics announced promising Phase I data for gavo-cel in mesothelin-expression that points toward effects in multiple solid tumors, especially ovarian cancer.
